OncRef

Clinical Trial: NCT03016871

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:City of Hope Medical Center
Information Provided By:City of Hope Medical Center
Last Update Posted:2026-08-25

Study Overview

Brief Summary

This phase II trial studies the side effects of nivolumab and to see how well it works when given together with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin lymphoma that has come back (relapsed) and does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies such as nivolumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ifosfamide, carboplatin and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab, ifosfamide, carboplatin and etoposide may work better in treating patients with Hodgkin lymphoma.

Official Title

A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)

Conditions

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma

Intervention / Treatment

  • Drug: Carboplatin
  • Drug: Etoposide
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Biological: Nivolumab

Other Study ID Numbers

  • 16403
  • NCI-2016-02038
  • 16403

Start Date (Actual)

2017-04-24

Primary Completion Date (Actual)

2024-01-30

Study Completion Date (Estimated)

2027-04-06

Enrollment (Actual)

78

Study Type

Interventional

Phase

Phase 2